Octapharma
| Company type | Private |
|---|---|
| Industry | Pharmaceutical Industry |
| Founded | 1983 |
| Headquarters | , |
Number of locations | 45 |
| Products | octaplas, octagam,octagam10%, octanate, octanineF, octaplex, octavi SD Optimum, octalbin, uniplas, rhesonativ, aunativ, gammonativ, atenativ, gammanorm, nanotiv, octonativ, octanine F, nuwiq, wilate See complete products listing. |
| Revenue | Euro 1.513 billion (2015)[1] |
Number of employees | 6,213 (2015)[2] |
| Website | www.octapharma.com |
Octapharma AG is the largest privately owned human protein products manufacturer in the world. Founded in 1983 by Wolfgang Marguerre, Octapharma employs 6,213 people globally. Octapharma is owned by Wolfgang Marguerre and his three children, two of whom, Frederic Marguerre and Tobias Marguerre, sit on the management board. Octapharma's core business is the development and production of human proteins from human blood plasma and human cell-lines. It is headquartered in Lachen, Switzerland.
Products
Patients in 105 countries are treated with products in the following therapeutic areas:
- Haematology: high-purity coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease
- Immunotherapy : immunomodulation or immunoglobulin replacement therapy for the treatment of immune-mediated diseases and deficiencies (immune disorders including autoimmune diseases and antibody deficiency) by inducing, enhancing, or suppressing an immune response.
- Critical Care: human plasma and protein products for treating critically ill or injured patients in intensive care and emergency medicine settings.
History
Octapharma was founded in 1983 on the principle of enhancing safety for patients. In the name Octapharma, the “octa” is derived from the Greek word for eight, named after the factor which is deficient in haemophilia A patients. Octapharma’s inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.
The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines.
Research and Development
Current R&D Projects (April 2014)
- Fully pharmaceutically licensed, SD-treated, freeze-dried, non-blood-type-specific plasma in bags
- A new Fibrinogen product
- Next generation Immunoglobulin
- A human growth factor product
- G-CSF (Granulocyte colony-stimulating factor, long acting)
- Alpha-1-Antitrypsin
- C1-Esterase-Inhibitor
- Human coagulation factor VII
Production
Octapharma converts source plasma into plasma protein products through fractionation and processing. Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico.
Octapharma owns plasma centres in Europe and the United States. To fulfil increasing global demand and to exceed its goals, the company is increasing plasma availability by sourcing higher volumes of plasma and increasing the capacity of production plants to convert more source plasma into product.
Notes and references
- ^ Annual report 2015 http://www.octapharma.com/en/about/newsroom/annual-reports.html
- ^ Annual report 2015 http://www.octapharma.com/en/about/newsroom/annual-reports.html
- ^ Octapharma Website http://www.octapharma.com/en/patients/diseases-therapies.html
See also
External links
| International | |
|---|---|
| National | |
